Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (101-110 of 1,833) with videos related to

Pageof 184
Sort By:
Mabs|May 6, 2017
Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal useFiona Sewell, Kathryn Chapman, Jessica Couch, et al.
Mabs|April 11, 2018
Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approachAlison Betts, Anne Keunecke, Tamara J van Steeg, et al.
Mabs|January 13, 2010
mAb therapeutic products and risk managementJanice M Reichert
Mabs|January 13, 2010
Letter from the editorJanice M Reichert
Mabs|January 13, 2010
TocilizumabAdith Venkiteshwaran
Mabs|January 13, 2010
CanakinumabEugen Dhimolea
Mabs|January 13, 2010
Regulation of T cell response by blocking the ICOS signal with the B7RP-1-specific small antibody fragment isolated from human antibody phage libraryMasatoshi Maeda, Yuji Ito, Takaaki Hatanaka, et al.
Mabs|January 14, 2010
Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonismClaire L Dobson, Sarah Main, Philip Newton, et al.
Mabs|January 14, 2010
Keystone Symposium on Antibodies as Drugs: March 27-April 1, 2009, Whistler, BC CAThierry Wurch, Christel Larbouret, Bruno Robert
Mabs|January 14, 2010
OfatumumabBodi Zhang
Pageof 184

Showing results (101-110 of 1,833) with videos related to

Sort By:
Pageof 184
Mabs|May 6, 2017
Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal useFiona Sewell, Kathryn Chapman, Jessica Couch, et al.
Mabs|April 11, 2018
Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approachAlison Betts, Anne Keunecke, Tamara J van Steeg, et al.
Mabs|January 13, 2010
mAb therapeutic products and risk managementJanice M Reichert
Mabs|January 13, 2010
Letter from the editorJanice M Reichert
Mabs|January 13, 2010
TocilizumabAdith Venkiteshwaran
Mabs|January 13, 2010
CanakinumabEugen Dhimolea
Mabs|January 13, 2010
Regulation of T cell response by blocking the ICOS signal with the B7RP-1-specific small antibody fragment isolated from human antibody phage libraryMasatoshi Maeda, Yuji Ito, Takaaki Hatanaka, et al.
Mabs|January 14, 2010
Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonismClaire L Dobson, Sarah Main, Philip Newton, et al.
Mabs|January 14, 2010
Keystone Symposium on Antibodies as Drugs: March 27-April 1, 2009, Whistler, BC CAThierry Wurch, Christel Larbouret, Bruno Robert
Mabs|January 14, 2010
OfatumumabBodi Zhang
Pageof 184